Floatz logo

Campath

CD40 Ligand Deficiency

Paul SzabolcsPhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the CD40 Ligand Deficiency cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Paul Szabolcs
Phase 2CCC
Fludarabine
Paul Szabolcs
Phase 2CCC
Anti-Thymoglobulin, Rabbit
Paul Szabolcs
Phase 2CCC
Evomela
Paul Szabolcs
Phase 2CCC
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2CCC

View all 9 →

Same molecule, other indications

Campath is also rated in:

sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →